Safety and Tolerability, and PK of Sibeprenlimab in Chinese Healthy Subject

Phase 1 Completed 24 enrolled Otsuka Beijing Research Institute Otsuka Pharmaceutical Development & Commercialization, Inc. · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

A Trial to Assess the Pharmacokinetics, Safety and Tolerability, and Pharmacodynamics, of Sibeprenlimab Solution Administered Subcutaneously in Chinese Healthy Subjects

Timeline

Start: 2022-10-18
Primary completion: 2023-02-15
Completion: 2023-02-15

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sibeprenlimab	Monoclonal antibody	200 mg	Subcutaneous
Subject	Sibeprenlimab	Monoclonal antibody	400 mg	Subcutaneous
Subject	Sibeprenlimab	Monoclonal antibody	600 mg	Subcutaneous

Indications

No indication recorded.